TYK Medicines Keeps Share Capital Steady at 380.07 Million H Shares in May; Public Float Meets 25% Rule

Bulletin Express06-02

TYK Medicines, Inc. (PRC-incorporated, listed in Hong Kong) reported no change in its share structure for the month ended 31 May 2026, according to the Monthly Return filed on 2 June 2026.

Registered and Issued Share Capital • Registered share capital: 380.07 million ordinary H shares, each with a par value of RMB 1, unchanged from April. • Issued shares (excluding treasury stock): 380.07 million. • Treasury shares: none. • Total issued shares outstanding therefore remain 380.07 million.

Public Float Compliance The company confirmed compliance with the Hong Kong Main Board’s minimum public float requirement—25% of issued H shares—as of 31 May 2026.

Corporate Actions • No share issuances, cancellations, or repurchases occurred during the month. • No share options, warrants, convertible securities, or other equity-linked instruments were outstanding or exercised. • No Hong Kong Depositary Receipts were in issue.

Governance The return was signed by Executive Director, Chairman and Chief Executive Officer Mr Wu Yusheng, affirming the accuracy of the disclosed information.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104429351?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104429351","market":"hk","top_or_hot":-1,"title":"TYK Medicines Keeps Share Capital Steady at 380.07 Million H Shares in May; Public Float Meets 25% Rule","media":"Bulletin Express","content":"<p>TYK Medicines, Inc. (PRC-incorporated, listed in Hong Kong) reported no change in its share structure for the month ended 31 May 2026, according to the Monthly Return filed on 2 June 2026.</p>\n<p>Registered and Issued Share Capital  \n• Registered share capital: 380.07 million ordinary H shares, each with a par value of RMB 1, unchanged from April.  \n• Issued shares (excluding treasury stock): 380.07 million.  \n• Treasury shares: none.  \n• Total issued shares outstanding therefore remain 380.07 million.</p>\n<p>Public Float Compliance  \nThe company confirmed compliance with the Hong Kong Main Board’s minimum public float requirement—25% of issued H shares—as of 31 May 2026.</p>\n<p>Corporate Actions  \n• No share issuances, cancellations, or repurchases occurred during the month.  \n• No share options, warrants, convertible securities, or other equity-linked instruments were outstanding or exercised.  \n• No Hong Kong Depositary Receipts were in issue.</p>\n<p>Governance  \nThe return was signed by Executive Director, Chairman and Chief Executive Officer Mr Wu Yusheng, affirming the accuracy of the disclosed information.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK Medicines Keeps Share Capital Steady at 380.07 Million H Shares in May; Public Float Meets 25% Rule</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK Medicines Keeps Share Capital Steady at 380.07 Million H Shares in May; Public Float Meets 25% Rule\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-02 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK Medicines, Inc. (PRC-incorporated, listed in Hong Kong) reported no change in its share structure for the month ended 31 May 2026, according to the Monthly Return filed on 2 June 2026.</p>\n<p>Registered and Issued Share Capital  \n• Registered share capital: 380.07 million ordinary H shares, each with a par value of RMB 1, unchanged from April.  \n• Issued shares (excluding treasury stock): 380.07 million.  \n• Treasury shares: none.  \n• Total issued shares outstanding therefore remain 380.07 million.</p>\n<p>Public Float Compliance  \nThe company confirmed compliance with the Hong Kong Main Board’s minimum public float requirement—25% of issued H shares—as of 31 May 2026.</p>\n<p>Corporate Actions  \n• No share issuances, cancellations, or repurchases occurred during the month.  \n• No share options, warrants, convertible securities, or other equity-linked instruments were outstanding or exercised.  \n• No Hong Kong Depositary Receipts were in issue.</p>\n<p>Governance  \nThe return was signed by Executive Director, Chairman and Chief Executive Officer Mr Wu Yusheng, affirming the accuracy of the disclosed information.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02410","symbol_name":"同源康医药-B","start_time":0,"source_url":"","article_id":"1104429351","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104429351","pubTimestamp":1780397051,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TYK Medicines, Inc. (PRC-incorporated, listed in Hong Kong) reported no change in its share structure for the month ended 31 May 2026, according to the Monthly Return filed on 2 June 2026. Registered...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02410":"同源康医药-B"},"translate_title":"泰克医药5月股本稳定在3.8007亿股H股；公众持股量符合25%规则","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":1},"content_text":"TYK Medicines, Inc. (PRC-incorporated, listed in Hong Kong) reported no change in its share structure for the month ended 31 May 2026, according to the Monthly Return filed on 2 June 2026.\nRegistered and Issued Share Capital  \n• Registered share capital: 380.07 million ordinary H shares, each with a par value of RMB 1, unchanged from April.  \n• Issued shares (excluding treasury stock): 380.07 million.  \n• Treasury shares: none.  \n• Total issued shares outstanding therefore remain 380.07 million.\nPublic Float Compliance  \nThe company confirmed compliance with the Hong Kong Main Board’s minimum public float requirement—25% of issued H shares—as of 31 May 2026.\nCorporate Actions  \n• No share issuances, cancellations, or repurchases occurred during the month.  \n• No share options, warrants, convertible securities, or other equity-linked instruments were outstanding or exercised.  \n• No Hong Kong Depositary Receipts were in issue.\nGovernance  \nThe return was signed by Executive Director, Chairman and Chief Executive Officer Mr Wu Yusheng, affirming the accuracy of the disclosed information.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104429351","isCrawlerRequest":true}